Value Partners, Insilico Medicine Plan AI, Life Sciences CVC Fund

MT Newswires Live
08/19

Value Partners Group (HKG:0806), Insilico Medicine (HKG:3696), Shanghai Pudong Development Group, and Pudong Construction plan to jointly establish a RMB-denominated corporate venture capital fund.

The fund will focus on artificial intelligence and life sciences, according to a statement on Tuesday.

Value Partners' onshore private fund manager will serve as the fund's general partner and manager.

The parties plan to combine capital and industry resources to invest across the AI and life sciences ecosystem.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10